Alitair Announces Notice of Patent Allowance for its Platform Drug Delivery Technology, REA

MORRISTOWN, N.J., Apr 12, 2012 (BUSINESS WIRE) -- Alitair Pharmaceuticals, Inc., a mid-stage pharmaceutical company with multiple respiratory product candidates in development, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ion exchange resin platform drug delivery technology, REA™. Alitair has out-licensed two product candidates utilizing its REA™ platform technology, and additional product candidates are available for out-licensing.

"Our propriety ion exchange resin delivery platform can be utilized across a range of therapeutic classes and with many different molecules," stated Alitair President and CEO, William W. Howard, Ph.D. "The REA™ platform technology allows us to improve upon currently available therapies and create new oral-solid formulations with less frequent dosing schedules, both of which have been shown to improve patient adherence."

"Receiving this Notice of Allowance is an important milestone in our product development strategy and the growth of Alitair," continued Howard. "We will continue to pursue additional patent protection in the U.S. and in key markets around the world. This Notice of Allowance from the PTO and our equally strong International Preliminary Examination Report (IPER) means that we will have a truly global patent portfolio in a short time. We are also actively seeking funding and development partners to build on the momentum we've created and advance our product development programs."

About Alitair Pharmaceuticals:

Alitair Pharmaceuticals, Inc. discovers, invents, and develops medicines for the treatment of respiratory illnesses. Alitair has out-licensed two prescription cough candidates that use its proprietary ion-exchange resin technology, REA™, and other product candidates are available for out-licensing. Additional information about Alitair is available on the Alitair website at www.alitair.com .

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.